1. Home
  2. TARS vs VCEL Comparison

TARS vs VCEL Comparison

Compare TARS & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tarsus Pharmaceuticals Inc.

TARS

Tarsus Pharmaceuticals Inc.

HOLD

Current Price

$78.18

Market Cap

2.7B

Sector

Health Care

ML Signal

HOLD

Logo Vericel Corporation

VCEL

Vericel Corporation

HOLD

Current Price

$39.87

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TARS
VCEL
Founded
2016
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
2.4B
IPO Year
2020
1996

Fundamental Metrics

Financial Performance
Metric
TARS
VCEL
Price
$78.18
$39.87
Analyst Decision
Buy
Strong Buy
Analyst Count
6
5
Target Price
$89.00
$57.75
AVG Volume (30 Days)
705.3K
439.6K
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
48.21
60.00
EPS
N/A
N/A
Revenue
$451,360,000.00
$276,259,000.00
Revenue This Year
$56.43
$19.40
Revenue Next Year
$30.19
$18.24
P/E Ratio
N/A
N/A
Revenue Growth
146.71
16.45
52 Week Low
$48.79
$28.95
52 Week High
$91.53
$49.32

Technical Indicators

Market Signals
Indicator
TARS
VCEL
Relative Strength Index (RSI) 58.64 40.84
Support Level $77.14 $35.45
Resistance Level $84.66 $41.25
Average True Range (ATR) 3.77 1.17
MACD -0.04 -0.17
Stochastic Oscillator 47.52 40.51

Price Performance

Historical Comparison
TARS
VCEL

About TARS Tarsus Pharmaceuticals Inc.

Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.

About VCEL Vericel Corporation

Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.

Share on Social Networks: